Free Trial
NASDAQ:IRD

Opus Genetics (IRD) Stock Price, News & Analysis

Opus Genetics logo
$1.19 -0.01 (-0.83%)
Closing price 04:00 PM Eastern
Extended Trading
$1.21 +0.02 (+2.02%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Opus Genetics Stock (NASDAQ:IRD)

Key Stats

Today's Range
$1.18
$1.23
50-Day Range
$0.91
$1.22
52-Week Range
$0.65
$1.75
Volume
109,161 shs
Average Volume
187,822 shs
Market Capitalization
$71.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33
Consensus Rating
Buy

Company Overview

Opus Genetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

IRD MarketRank™: 

Opus Genetics scored higher than 46% of companies evaluated by MarketBeat, and ranked 630th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Opus Genetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Opus Genetics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Opus Genetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Opus Genetics are expected to grow in the coming year, from ($1.22) to ($1.03) per share.

  • Price to Book Value per Share Ratio

    Opus Genetics has a P/B Ratio of 4.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Opus Genetics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for IRD.
  • Dividend Yield

    Opus Genetics does not currently pay a dividend.

  • Dividend Growth

    Opus Genetics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for IRD.
  • News Sentiment

    Opus Genetics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Opus Genetics this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for IRD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Opus Genetics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Opus Genetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.60% of the stock of Opus Genetics is held by insiders.

  • Percentage Held by Institutions

    Only 14.97% of the stock of Opus Genetics is held by institutions.

  • Read more about Opus Genetics' insider trading history.
Receive IRD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opus Genetics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRD Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
See More Headlines

IRD Stock Analysis - Frequently Asked Questions

Opus Genetics' stock was trading at $1.19 at the beginning of the year. Since then, IRD shares have increased by 0.0% and is now trading at $1.19.

Opus Genetics, Inc. (NASDAQ:IRD) issued its earnings results on Wednesday, August, 13th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.13. The business earned $2.88 million during the quarter, compared to analyst estimates of $4.27 million. Opus Genetics had a negative net margin of 377.89% and a negative trailing twelve-month return on equity of 384.33%.

Opus Genetics' top institutional shareholders include BIOS Capital Management LP (6.17%), Nantahala Capital Management LLC (5.61%), Opaleye Management Inc. (2.04%) and Mink Brook Asset Management LLC (2.01%).
View institutional ownership trends
.

Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/13/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IRD
Previous Symbol
NASDAQ:IRD
CIK
1228627
Employees
14
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$6.00
Potential Upside/Downside
+508.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$57.53 million
Net Margins
-377.89%
Pretax Margin
-377.89%
Return on Equity
-384.33%
Return on Assets
-148.90%

Debt

Debt-to-Equity Ratio
0.06
Current Ratio
1.90
Quick Ratio
1.90

Sales & Book Value

Annual Sales
$15.42 million
Price / Sales
4.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.29 per share
Price / Book
4.16

Miscellaneous

Outstanding Shares
59,908,000
Free Float
55,954,000
Market Cap
$72.19 million
Optionable
N/A
Beta
0.01
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:IRD) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners